389 related articles for article (PubMed ID: 8490911)
21. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies.
Lopez JB; Royan GP; Lakhwani MN; Mahadaven M; Timor J
Int J Biol Markers; 1999; 14(3):172-7. PubMed ID: 10569140
[TBL] [Abstract][Full Text] [Related]
22. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
[TBL] [Abstract][Full Text] [Related]
23. Serum values of CA72.4 in patients with gastrointestinal system tumors comparison with CEA and CA 19.9.
Yasasever V; Sengün Z; Saydan N; Onat H; Dalay N
Eur J Gynaecol Oncol; 1992; 13(5):403-8. PubMed ID: 1486919
[TBL] [Abstract][Full Text] [Related]
24. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
25. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
van Dalen A
Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
[TBL] [Abstract][Full Text] [Related]
26. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
27. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
[TBL] [Abstract][Full Text] [Related]
28. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma.
Andicoechea A; Vizoso F; Alexandre E; Martínez A; Cruz Díez M; Riera L; Martinez E; Ruibal A
World J Surg; 1999 Mar; 23(3):227-31; discussion 231-2. PubMed ID: 9933690
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
31. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
32. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
33. Significance of CA 72-4 in colorectal carcinoma. Comparison with CEA and CA 19-9.
Fernández-Fernández L; Tejero E; Tieso A
Eur J Surg Oncol; 1995 Aug; 21(4):388-90. PubMed ID: 7664904
[TBL] [Abstract][Full Text] [Related]
34. Preoperative serum levels of CEA and CA 242 in colorectal cancer.
Carpelan-Holmström M; Haglund C; Kuusela P; Järvinen H; Roberts PJ
Br J Cancer; 1995 Apr; 71(4):868-72. PubMed ID: 7710956
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of serum tumor markers in the diagnosis of malignant intestinal occlusion. A prospective observational study.
Marrelli D; Caruso S; Neri A; Pedrazzani C; Capuano L; Mazzei MA; Roviello F
Int J Biol Markers; 2011; 26(1):58-64. PubMed ID: 21279957
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
37. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
38. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
Barillari P; Bolognese A; Chirletti P; Cardi M; Sammartino P; Stipa V
Dis Colon Rectum; 1992 May; 35(5):471-6. PubMed ID: 1568399
[TBL] [Abstract][Full Text] [Related]
39. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
40. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
Safi F; Kuhns V; Beger HG
Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
